Twist Bioscience (NASDAQ:TWST) SVP Sells 291 Shares

Twist Bioscience Corporation (NASDAQ:TWST) SVP Paula Green sold 291 shares of the company’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $87.32, for a total value of $25,410.12. Following the completion of the sale, the senior vice president directly owned 120,414 shares in the company, valued at $10,514,550.48. This trade represents a 0.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Twist Bioscience Price Performance

Shares of TWST stock traded up $6.35 during mid-day trading on Wednesday, reaching $91.35. The stock had a trading volume of 2,440,610 shares, compared to its average volume of 1,477,205. The company has a market cap of $5.69 billion, a P/E ratio of -68.68 and a beta of 2.23. The company has a current ratio of 2.70, a quick ratio of 2.42 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $93.80. The business has a 50-day simple moving average of $64.56 and a 200 day simple moving average of $50.23.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, May 4th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.22). The business had revenue of $110.72 million during the quarter, compared to analysts’ expectations of $107.64 million. Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.Twist Bioscience’s quarterly revenue was up 19.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.66) earnings per share. On average, sell-side analysts anticipate that Twist Bioscience Corporation will post -2.02 earnings per share for the current year.

Institutional Trading of Twist Bioscience

Hedge funds have recently added to or reduced their stakes in the business. Quarry LP purchased a new position in Twist Bioscience in the third quarter valued at approximately $28,000. Western Wealth Management LLC purchased a new stake in Twist Bioscience during the first quarter worth approximately $31,000. Strs Ohio purchased a new stake in Twist Bioscience during the first quarter worth approximately $33,000. Strategic Advocates LLC increased its position in shares of Twist Bioscience by 562.7% in the fourth quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock worth $34,000 after acquiring an additional 906 shares in the last quarter. Finally, SBI Securities Co. Ltd. increased its position in shares of Twist Bioscience by 68.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock worth $44,000 after acquiring an additional 571 shares in the last quarter.

Analyst Ratings Changes

Several brokerages recently issued reports on TWST. TD Cowen lifted their price objective on Twist Bioscience from $68.00 to $89.00 and gave the stock a “buy” rating in a research report on Monday, June 15th. Piper Sandler initiated coverage on Twist Bioscience in a report on Thursday, June 11th. They issued an “overweight” rating and a $85.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Friday, March 27th. Barclays increased their price objective on Twist Bioscience from $65.00 to $95.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Leerink Partners set a $80.00 price objective on Twist Bioscience in a research report on Friday, May 22nd. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $74.60.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.